Stockreport

Can Definium Therapeutics (DFTX) Turn GAD Prevalence And DT120 Breakthrough Status Into Durable Advantage? [Yahoo! Finance]

Definium Therapeutics, Inc. - Common Shares  (DFTX) 
PDF rose from 5.4% in 2020 to 6.6% in 2023, alongside advancing its lead candidate DT120 ODT, which has FDA Breakthrough Therapy Designation for GAD and is approaching poten [Read more]